Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 2Colonic Neoplasms 2Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Hepatocellular 1Carcinoma 1Adenocarcinoma 1

Interventions

Sorafenib 5lenvatinib 3sintilimab 2pembrolizumab 2halofantrine 2camrelizumab 2atezolizumab 2Immunotherapy 2Blood Specimen Collection 2Bevacizumab 2Antibodies 2trifluridine tipiracil drug combination 1trametinib 1toripalimab 1titanium silicide 1tislelizumab 1linifanib 1genexol-PM 1gadolinium ethoxybenzyl DTPA 1fluorocholine 1fisogatinib 1ficlatuzumab 1durvalumab 1bavituximab 1avelumab 1User-Centered Design 1Sunitinib 1Sufentanil 1Standard of Care 1Shadowing Technique, Histology 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Diseases × linifanib × Gastrointestinal × Clear all
NCT01009593 2012-09-10

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Abbott

Phase 3 Terminated
1,035 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡